The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug

Scandinavian Journal of Rheumatology

Volumn 41, Issue 1, 2012, Pages 1-9

  Soderlin M K ^a   Petersson, I F ^b   Geborek, P ^b  

^a Spenshult Rheumatology Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MONITORING; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMPLIFIED DISEASE ACTIVITY INDEX; SMOKING; SMOKING HABIT; SWEDEN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856495872     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.599073     Document Type: Article

References (32)

1. Turesson C, Schaid DJ, Weyand CM, Jacobsson LT, Goronzy JJ, Petersson IF, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2776-83. (Pubitemid 44497756)
2. Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M, et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006;45:734-40. (Pubitemid 43985343)
3. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000;27:630-7. (Pubitemid 30151338)
4. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA. Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 2005;23:861-6. (Pubitemid 43040515)
5. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75. (Pubitemid 46668455)
6. Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007;56:1446-53. (Pubitemid 46764072)
7. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anticyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007;9:R56.
8. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-65. (Pubitemid 44817065)
9. Mattey DL, Brownfield A, Dawes PT. Relationship between packyear history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol 2009;36:1180-7.
10. Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti- TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010;16:15-18.
11. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and TNF inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011;63:26-36.
12. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8. (Pubitemid 46657517)
13. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in Southern Sweden. Ann Rheum Dis 2002;61:793-8.
14. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
16. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50. (Pubitemid 28465539)
17. Gulfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis 2005;64:1186-9. (Pubitemid 41113354)
18. Gulfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord 2009;10:41.
19. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:507-13.
20. Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial openlabel phase of the SWEFOT trial. Ann Rheum Dis 2011;70:469-75.
21. Soderlin M, Petersson I, Bergman S, Svensson B. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol. Published online 22 February 2011. doi:10.3109/03009742.2010. 541495.
22. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997;56:463-9. (Pubitemid 27396032)
23. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of1839 patients in Southern Sweden. Ann Rheum Dis 2008;67:37-42.
24. Nyhall-Wahlin BM, Jacobsson LT, Petersson IF, Turesson C. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis. Ann Rheum Dis 2006;65:601-6.
25. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007;131:1557-66. (Pubitemid 46762366)
26. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. Rheumatology (Oxford) 2008;47:849-54. (Pubitemid 351796371)
27. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009;60:2248-56.
28. Soderlin MK, Jacobsson LT, Petersson IF, Englund M, Saxne T, Geborek P. Differences in longitudinal disease and treatment characteristics of patients with rheumatoid arthritis replying and not replying to a postal questionnaire. Experience from a biologics register in Southern Sweden. J Rheumatol 2009; 36:1166-9.
29. Barchielli A, Balzi D. Nine-year follow-up of a survey on smoking habits in Florence (Italy): higher mortality among non-responders. Int J Epidemiol 2002;31:1038-42. (Pubitemid 35446880)
30. Bergstrand R, Vedin A, Wilhelmsson C, Wilhelmsen L. Bias due to non-participation and heterogenous sub-groups in population surveys. J Chronic Dis 1983;36:725-8. (Pubitemid 14246893)
31. Geborek P, Nitelius E, Noltorp S, Petri H, Jacobsson L, Larsson L, et al. Population based studies of biological antirheumatic drug use in Southern Sweden: comparison with pharmaceutical sales. Ann Rheum Dis 2005;64:1805-7. (Pubitemid 41667171)
32. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:495-9.